Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of MT10109L for Glabellar and Lateral Canthal Lines
NCT04157686Phase 3Completed
- Sponsor
- Medytox Inc.
- Start
- Oct 2019
- Primary completion
- Feb 2023
- Modality
- Bacterial Toxin Conjugates
- Countries
- 6
01
Overview
A Phase 3 trial of nivobotulinumtoxinA in glabellar lines, lateral canthal rhytides, sponsored by Medytox Inc.. Started Oct 2019; status: completed.
02
Drugs
nivobotulinumtoxinA
03
Conditions
glabellar lineslateral canthal rhytides
Beyond the preview
Go deeper on NCT04157686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04157686.